Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis. Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M Neurologia. 2013 Oct 22. PMID: 24161412. Abstract CommentRecommendBookmarkWatch